Parnell Pharmaceuticals Holdings (NASDAQ: PARN) and Allergan PLC. (NYSE:AGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.
Valuation & Earnings
This table compares Parnell Pharmaceuticals Holdings and Allergan PLC.’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Parnell Pharmaceuticals Holdings | N/A | N/A | N/A | N/A | N/A |
| Allergan PLC. | $15.07 billion | 4.97 | $6.15 billion | $28.15 | 7.96 |
Allergan PLC. has higher revenue and earnings than Parnell Pharmaceuticals Holdings.
Risk & Volatility
Parnell Pharmaceuticals Holdings has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, Allergan PLC. has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Parnell Pharmaceuticals Holdings and Allergan PLC., as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Parnell Pharmaceuticals Holdings | 0 | 0 | 0 | 0 | N/A |
| Allergan PLC. | 0 | 5 | 13 | 0 | 2.72 |
Allergan PLC. has a consensus target price of $277.76, suggesting a potential upside of 24.01%. Given Allergan PLC.’s higher possible upside, analysts clearly believe Allergan PLC. is more favorable than Parnell Pharmaceuticals Holdings.
Profitability
This table compares Parnell Pharmaceuticals Holdings and Allergan PLC.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Parnell Pharmaceuticals Holdings | -130.46% | -83.86% | -43.24% |
| Allergan PLC. | 79.17% | 7.37% | 4.17% |
Institutional & Insider Ownership
16.9% of Parnell Pharmaceuticals Holdings shares are owned by institutional investors. Comparatively, 83.6% of Allergan PLC. shares are owned by institutional investors. 0.4% of Allergan PLC. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Dividends
Allergan PLC. pays an annual dividend of $2.80 per share and has a dividend yield of 1.3%. Parnell Pharmaceuticals Holdings does not pay a dividend. Allergan PLC. pays out 9.9% of its earnings in the form of a dividend.
Summary
Allergan PLC. beats Parnell Pharmaceuticals Holdings on 10 of the 11 factors compared between the two stocks.
Parnell Pharmaceuticals Holdings Company Profile
Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The Company operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. It augments its pharmaceutical products with its FETCH and mySYNCH software platforms. It offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. It has a nutraceutical product, Glyde. It also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. It is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
Allergan PLC. Company Profile
Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.
Receive News & Ratings for Parnell Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parnell Pharmaceuticals Holdings Ltd and related companies with MarketBeat.com's FREE daily email newsletter.
